Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
Eloy E OrdayaEibhlin M HigginsPaschalis VergidisRaymund R RazonableElena BeamPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
In this cohort of OHT recipients, no patients developed severe cardiovascular events related to tix-cil. The high incidence of breakthrough COVID-19 could be due to the reduced activity of tix-cil against current circulating SARS-CoV-2 Omicron variants. These results emphasize the need for a multimodal prevention strategy against SARS-CoV-2 in these high-risk patients.
Keyphrases
- sars cov
- cardiovascular events
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- coronary artery disease
- cardiovascular disease
- coronavirus disease
- heart failure
- respiratory syndrome coronavirus
- gene expression
- type diabetes
- dna methylation
- patient reported outcomes
- risk factors
- copy number